Astellas/Pfizer Settle Dispute Over Lipitor Rights In Japan
This article was originally published in The Pink Sheet Daily
Executive Summary
Firms also gain Japanese marketing approval for celecoxib for treatment of inflammation and pain associated with rheumatoid arthritis and osteoarthritis.
You may also be interested in...
Astellas VP-Business Development Masaki Doi: An Interview With "The Pink Sheet" DAILY (Part 1 of 2)
"The Pink Sheet" DAILY visited recently with Astellas Pharma VP-Business Development Masaki Doi at the company's headquarters in Tokyo to talk about the Japanese pharma's global licensing strategy and the changing paradigm of Japanese deal flow.
Astellas VP-Business Development Masaki Doi: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
Japanese pharma exec discusses Astellas’ global licensing strategy, the FibroGen deal, and the changing paradigm of Japanese deal flow.
Astellas VP-Business Development Masaki Doi: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
Japanese pharma exec discusses Astellas’ global licensing strategy, the FibroGen deal, and the changing paradigm of Japanese deal flow.